These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38093617)

  • 1. A new alternative approach to management of acute phase Peyronie's disease: low intensity extracorporeal shockwave therapy and platelet-rich plasma.
    Karakose A; Yitgin Y
    Minerva Urol Nephrol; 2024 Jun; 76(3):367-372. PubMed ID: 38093617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shockwave Therapy in the Treatment of Peyronie's Disease.
    Krieger JR; Rizk PJ; Kohn TP; Pastuszak A
    Sex Med Rev; 2019 Jul; 7(3):499-507. PubMed ID: 30926460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Low-intensity extracorporeal shockwave therapy for Peyronie's disease: A preliminary study of 32 cases].
    Li PC; Chen X; Zhu XB; Shi T; Song F; Huang HW; Zhang XS
    Zhonghua Nan Ke Xue; 2018 Apr; 24(4):340-344. PubMed ID: 30168955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-intensity laser diode plus extracorporeal shock wave therapy: a new treatment strategy in the management of Peyronie's disease.
    Dell'Atti L; Ronchi P
    World J Urol; 2023 Sep; 41(9):2563-2568. PubMed ID: 37490060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracorporeal Shockwave Therapy in Peyronie's Disease: Systematic Review and Meta-Analysis.
    Bakr AM; El-Sakka AI
    J Sex Med; 2021 Oct; 18(10):1705-1714. PubMed ID: 34511369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of the Current Status of Low Intensity Extracorporeal Shockwave Therapy (Li-ESWT) in Erectile Dysfunction (ED), Peyronie's Disease (PD), and Sexual Rehabilitation After Radical Prostatectomy With Special Focus on Technical Aspects of the Different Marketed ESWT Devices Including Personal Experiences in 350 Patients.
    Porst H
    Sex Med Rev; 2021 Jan; 9(1):93-122. PubMed ID: 32499189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial.
    Palmieri A; Imbimbo C; Creta M; Verze P; Fusco F; Mirone V
    Int J Androl; 2012 Apr; 35(2):190-5. PubMed ID: 22085227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracorporeal shockwave therapy for Peyronie's disease: an alternative treatment?
    Poulakis V; Skriapas K; de Vries R; Dillenburg W; Ferakis N; Witzsch U; Melekos M; Becht E
    Asian J Androl; 2006 May; 8(3):361-6. PubMed ID: 16625288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of extracorporeal shockwave therapy for erectile dysfunction and Peyronie's disease on reproductive and hormonal testicular function.
    Manfredi C; Arcaniolo D; Amicuzi U; Spirito L; Napolitano L; Crocerossa F; Paoletta M; Gisone S; Cirillo P; Crocetto F; Bellastella G; De Sio M; Imbimbo C
    Andrology; 2022 Oct; 10(7):1368-1375. PubMed ID: 35909300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant daily therapy with L-arginine 2,500 mg and tadalafil 5 mg increases efficacy and duration of benefits of low-intensity extracorporeal shock wave therapy for erectile dysfunction: A prospective, randomized, single-blinded study with 1-year follow-up.
    Gallo L; Pecoraro S; Sarnacchiaro P
    Investig Clin Urol; 2022 Jan; 63(1):83-91. PubMed ID: 34983126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease.
    Palmieri A; Imbimbo C; Longo N; Fusco F; Verze P; Mangiapia F; Creta M; Mirone V
    Eur Urol; 2009 Aug; 56(2):363-9. PubMed ID: 19473751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of extracorporeal shock wave therapy for acute Peyronie's disease: a 10-year retrospective analysis.
    Spirito L; Manfredi C; La Rocca R; Napolitano L; Preto M; Di Girolamo A; Arcaniolo D; De Sio M; Creta M; Longo N
    Int J Impot Res; 2024 Apr; 36(2):135-139. PubMed ID: 36788352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-intensity extracorporeal shock wave therapy for Peyronie's disease: a single-center experience.
    Abdessater M; Akakpo W; Kanbar A; Parra J; Seisen T; Chartier-Kastler E; Drouin SJ; Roupret M
    Asian J Androl; 2022; 24(1):45-49. PubMed ID: 34045390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An alternative non-invasive treatment for Peyronie's disease.
    Claro JA; Passerotti CC; Figueiredo Neto AC; Nardozza A; Ortiz V; Srougi M
    Int Braz J Urol; 2004; 30(3):199-204; discussion 204. PubMed ID: 15689246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie's disease: a retrospective comparative analysis.
    Spirito L; Manfredi C; La Rocca R; Napolitano L; Di Girolamo A; Capece M; Trama F; Sciorio C; Sokolakis I; Creta M; Arcaniolo D
    Int J Impot Res; 2024 Apr; 36(2):129-134. PubMed ID: 36513814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease.
    Prieto Castro RM; Leva Vallejo ME; Regueiro Lopez JC; Anglada Curado FJ; Alvarez Kindelan J; Requena Tapia MJ
    BJU Int; 2003 Apr; 91(6):522-4. PubMed ID: 12656907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of long term sildenafil on the acute phase of Peyronie's disease in a combination treatment.
    Topcuoglu M; Çakan M
    Arch Ital Urol Androl; 2022 Sep; 94(3):319-322. PubMed ID: 36165478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current treatment and management of the acute phase of Peyronies's disease].
    Vanni AJ; Bennett NE
    Arch Esp Urol; 2009 Oct; 62(8):614-22. PubMed ID: 19893134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracorporeal shock wave therapy (ESWT) in urology: a systematic review of outcome in Peyronie's disease, erectile dysfunction and chronic pelvic pain.
    Fojecki GL; Tiessen S; Osther PJ
    World J Urol; 2017 Jan; 35(1):1-9. PubMed ID: 27108421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated recommendations on the therapeutic role of extracorporeal shock wave therapy for peyronie's disease: systematic review and meta-analysis.
    Wang X; Liu H; Tang G; Wu G; Chu Y; Wu J; Cui Y
    BMC Urol; 2023 Sep; 23(1):145. PubMed ID: 37700253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.